HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

CompletedOBSERVATIONAL
Enrollment

389

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Urothelial Carcinoma
Trial Locations (23)

1090

AKH Wien, Vienna

10029

ICAHN School of Medicine at Mount Sinai,, New York

23538

University Hospital Lübeck, Lübeck

27710

Duke Cancer Institute - School of Medicine, Durham

28204

Levine Cancer Institute, Charlotte

33075

Chu Bordeaux Hopital Saint Andre, Bordeaux

37232

Vanderbilt - Ingram Cancer Center, Nashville

47805

Alexianer Krefeld GmbH, Krefeld

57104

Avera Cancer Institute Center, Sioux Falls

69373

Centre Léon Bérard, Lyon

69495

CHU LYON, Pierre-Bénite

70174

Stuttgart Hospital, Stuttgart

75674

Institut Mutualiste Montsouris, Paris

76000

CHU de Rouen., Rouen

80045

University of Colorado Hospital, Aurora

85054

Mayo Clinic, Phoenix

85925

Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon

90404

University of California Los Angeles, Santa Monica

92150

Foch Hospital, Suresnes

92868

University of California Irvine, Orange

94143

University of California San Francisco, San Francisco

94394

Stanford Cancer Institute - School of Medicine, Palo Alto

06189 Cedex 2

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Seagen, a wholly owned subsidiary of Pfizer

INDUSTRY